What the Agelity® human study found
This peer-reviewed human study, published in Nutrients, characterized — for the first time — the oral pharmacokinetics and endocrine effects of Agelity®, Advenion Nutrition’s standardized D-Pinitol ingredient, in fasting healthy volunteers. The research reported that Agelity® is efficiently absorbed after oral administration, shows an extended absorption phase, and presents a long plasma half-life exceeding five hours, consistent with sustained physiological activity.
The study reported that Agelity® was associated with a lower circulating insulin response while maintaining stable blood glucose, consistent with an insulin-efficient metabolic profile in humans. These effects were accompanied by coordinated endocrine responses, including increased glucagon and ghrelin secretion, without altering glucose homeostasis or pituitary hormone balance, and Agelity® was well tolerated in this study.
This publication characterizes Agelity® — a standardized, traceable source of D-Pinitol — as an orally active metabolic modulator that supports healthy insulin and glucose balance, providing human clinical support for Agelity® in metabolic wellness and healthy aging applications. By evaluating the specific Agelity® ingredient rather than generic D-Pinitol, the study reinforces the value of standardization and analytical control.
This study evaluated pharmacokinetic and endocrine responses in healthy human volunteers. These statements have not been evaluated by the Food and Drug Administration. Agelity® is an ingredient and is not intended to diagnose, treat, cure, or prevent any disease.